Bogers W A, Meems L
Eur J Clin Pharmacol. 1983;24(3):301-5. doi: 10.1007/BF00610045.
Nineteen out-patients with moderate to severe essential hypertension were treated daily for 3 years, with an average dose of 13 mg endralazine, a new peripheral vasodilator, in free combination with pindolol 3 x 5 mg. The blood pressure showed a statistically significant reduction from 172/110 mmHg to 154/92 mmHg after treatment for 3 years. Tachyphylaxis was not observed during the 3 years period. Oedema was the most frequent side-effect, but it disappeared spontaneously. No difference in efficacy and tolerance between slow and fast acetylators was found. Only 2 patients developed a weak positive antinuclear antibody titre, which disappeared spontaneously from one during continued treatment. No clinical evidence of a systemic lupus erythematosus-like syndrome was noted. It is concluded that the differences between endralazine and hydralazine in dosage and metabolism may explain the lower immunogenic activity of endralazine.
19例中重度原发性高血压门诊患者接受了为期3年的治疗，每日服用平均剂量为13毫克的恩屈嗪（一种新型外周血管扩张剂），并与3×5毫克的吲哚洛尔自由联合使用。治疗3年后，血压从172/110毫米汞柱降至154/92毫米汞柱，具有统计学显著差异。在这3年期间未观察到快速耐受性。水肿是最常见的副作用，但会自行消失。慢乙酰化者和快乙酰化者在疗效和耐受性方面未发现差异。只有2例患者抗核抗体滴度呈弱阳性，其中1例在持续治疗期间自行消失。未发现系统性红斑狼疮样综合征的临床证据。结论是，恩屈嗪和肼屈嗪在剂量和代谢方面的差异可能解释了恩屈嗪较低的免疫原活性。
